Conduit Pharmaceuticals Inc. Total Assets
Conduit Pharmaceuticals Inc. total assets. Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) holds total assets worth $3.50 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Conduit Pharmaceuticals Inc. (CDT) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Conduit Pharmaceuticals Inc. (2021–2025)
Total assets of Conduit Pharmaceuticals Inc. from 2021 to 2025. This chart illustrates how Conduit Pharmaceuticals Inc.'s total assets have evolved over time, based on quarterly financial data. See Conduit Pharmaceuticals Inc. stock quote for real-time trading data and today's change.
Conduit Pharmaceuticals Inc. - Asset Composition Analysis
Conduit Pharmaceuticals Inc. Total Assets Breakdown (December 2025)
Conduit Pharmaceuticals Inc. total assets breakdown as of December 2025. Conduit Pharmaceuticals Inc.'s total assets of $3.50 Billion consist of 38.1% current assets and 61.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $462.85 Million | 13.1% |
| Inventory | $402.35 Million | 11.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $399.80 Million | 11.3% |
| Goodwill | $1.04 Billion | 29.3% |
Asset Composition Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Conduit Pharmaceuticals Inc. current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Conduit Pharmaceuticals Inc.'s current assets represent 38.1% of total assets in 2025, a decrease from 48.9% in 2021.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 22.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 29.3% of total assets.
Conduit Pharmaceuticals Inc. Competitors by Total Assets
Key competitors of Conduit Pharmaceuticals Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Conduit Pharmaceuticals Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.14 | 1.45 | 0.54 |
| Quick Ratio | 1.49 | -86.65 | 0.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $741.05 Million | $1.97 Million | $-88.34K |
Conduit Pharmaceuticals Inc. - Advanced Valuation Insights
This section examines the relationship between Conduit Pharmaceuticals Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.02 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 84412.8% |
| Total Assets | $3.54 Billion |
| Market Capitalization | $2.72K USD |
Valuation Analysis
Below Book Valuation: The market values Conduit Pharmaceuticals Inc.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Conduit Pharmaceuticals Inc.'s assets grew by 84412.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual total assets of Conduit Pharmaceuticals Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.54 Billion | +84412.78% |
| 2024-12-31 | $4.19 Million | -41.96% |
| 2023-12-31 | $7.22 Million | +144380.00% |
| 2022-12-31 | $5.00K | -97.65% |
| 2021-12-31 | $213.12K | -- |
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more